Ye Weiguo

Chief Operating OfficerGYRE THERAPEUTICS, INC. (GYRE) · full profile →Form 4 · filed May 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$59K
Net Open-Market Flow
-$59K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 19, 2026Option exercise(M)9K$0.75$7K709K
May 19, 2026Sell(S)9K$6.37$58K700K
May 18, 2026Option exercise(M)200$0.75$150700K
May 18, 2026Sell(S)200$6.62$1K700K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 19, 2026Option exercise(M)9K$0927K
May 18, 2026Option exercise(M)200$0936K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-26-022235) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about GYRE insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001140361-26-022235"
Ask your agent
Use Arkolith to summarize insider buying and selling at GYRE THERAPEUTICS, INC.
over the last 90 days and cite the filings.